Exabis Library
Welcome to the e-CCO Library!
DOP81: Time to loss of efficacy among patients in remission following induction treatment with tofacitinib 10 mg BID who reduced tofacitinib dose or discontinued tofacitinib in OCTAVE Sustain
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP81: Unaffected ileal transcriptomics in Crohn's disease is associated with the response to anti-TNF therapy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP81: Unaffected ileal transcriptomics in Crohn's disease is associated with the response to anti-TNF therapy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP81: Utility of a simple blood test for mucosal healing monitoring is accurate in post-operative Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP81: Utility of a Simple Blood Test for Mucosal Healing Monitoring is Accurate in Post-Operative Crohn’s Disease
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP82 Macrophages in Crohn’s disease mesentery are predominantly inflammatory and produce calprotectin
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP82: Achievement of steroid-free remission in patients with moderately to severely active Crohn’s Disease during treatment with risankizumab
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP82: Biological Treatment Cycles in Crohn's Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP82: Biological Treatment Cycles in Crohn’s Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP82: Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: Post hoc analysis of the phase 2b/3 SELECTION study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP82: Direct and indirect costs of inflammatory bowel disease in the biological era; 10 years of follow-up in a Danish population-based inception cohort
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP82: Direct and indirect costs of inflammatory bowel disease in the biological era; ten years of follow up in a Danish population-based inception cohort
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP82: Macrophages in Crohn’s Disease mesentery are predominantly inflammatory and produce calprotectin
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP82: Macrophages in Crohn’s Disease mesentery are predominantly inflammatory and produce calprotectin
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP83 Intestinal fibrosis in Crohn’s disease patients is marked by up-regulation of innate immune cells and mucosal B cells
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP83: Association of FUT2 and ABO with Crohn’s disease in Koreans
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP83: Association of FUT2 and ABO with Crohn’s disease in Koreans
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP83: Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP83: Intestinal epithelium-specific deletion of the Aryl hydrocarbon Receptor (AhR) reduces intestinal Tight Junction permeability thereby hindering homeostatic antigen sampling and tolerogenic immune responses.
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP83: Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn’s Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM